Evommune ends EVO756 atopic dermatitis program

Evommune is ending development of EVO756 for atopic dermatitis after a failed Phase 2b trial, while continuing migraine studies and projecting cash runway into 2029.

Rhea-AI Filing Summary

Evommune, Inc. (EVMN) filed a prospectus supplement incorporating a Current Report that discloses top-line results from a Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe atopic dermatitis. The randomized, double-blind, placebo-controlled, dose-ranging study enrolled 121 adults over a 12-week treatment period with follow-up through Week 14 and did not meet its primary or secondary endpoints at any dose tested.

Based on these results, Evommune plans to cease development of EVO756 for atopic dermatitis but will continue to evaluate the drug in migraine prophylaxis. The company states that, given its revised clinical development plans, current cash, cash equivalents, and investments are expected to fund operations into 2029. The supplement also notes that Evommune’s common stock trades on the NYSE under the symbol EVMN, with a last reported sale price of $13.08 per share on September 8, 2026.

Positive

• Evommune projects its current cash, cash equivalents, and investments, based on revised clinical plans, will be sufficient to fund operations into 2029.
• The company will continue evaluating EVO756 in migraine prophylaxis, preserving a development path for the asset despite discontinuing its atopic dermatitis program.

Negative

• The Phase 2b trial of EVO756 in moderate-to-severe atopic dermatitis, enrolling 121 adults, did not meet the primary or secondary endpoints at any dose.
• Evommune plans to cease development of EVO756 for atopic dermatitis, removing this indication from the company’s clinical pipeline.

Filing Explained

The September 8 filing updates Evommune’s existing Form S-1 prospectus with the clinical event, but discloses no specific takedown terms, issuance, or proceeds; the registration therefore does not itself establish a sale.

Key Figures

Last reported share price: $13.08 per share Phase 2b trial enrollment: 121 adults Treatment duration: 12 weeks +3 more

6 metrics

Last reported share price $13.08 per share Evommune common stock on September 8, 2026

Phase 2b trial enrollment 121 adults Moderate-to-severe atopic dermatitis EVO756 trial

Treatment duration 12 weeks EVO756 Phase 2b atopic dermatitis trial treatment period

Follow-up duration Week 14 Follow-up endpoint for EVO756 Phase 2b trial

Cash runway Into 2029 Based on current cash, cash equivalents, investments, and revised clinical plans

Date of report September 8, 2026 Form 8-K event date incorporated into prospectus supplement

Key Terms

Prospectus supplement, Phase 2b, Atopic Dermatitis, migraine prophylaxis, +2 more

6 terms

Prospectus supplement regulatory

"This prospectus supplement updates, amends and supplements the prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Phase 2b medical

"top-line results from EVO756 Phase 2b Trial in Moderate-to-Severe"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

Atopic Dermatitis medical

"Phase 2b trial in Moderate-to-Severe Atopic Dermatitis"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

migraine prophylaxis medical

"The Company will continue to evaluate EVO756 in migraine prophylaxis"

Migraine prophylaxis means treatments taken regularly to prevent migraine attacks or make them less severe and frequent, rather than treating pain after an attack starts. For investors it signals a longer-term market—like selling preventive maintenance rather than one-off repairs—because effective, well-tolerated preventive therapies can drive steady prescription use, recurring revenue, and influence valuation based on trial results, adoption rates, and safety profiles.

forward-looking statements regulatory

"contains forward-looking statements which are subject to the safe harbor"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evommune (EVMN) announce about the EVO756 Phase 2b atopic dermatitis trial?

Evommune reported top-line results from a randomized, double-blind, placebo-controlled Phase 2b trial of EVO756 in moderate-to-severe atopic dermatitis. The study did not meet primary or secondary endpoints at any dose, leading the company to end development of this indication.

How many patients were enrolled in Evommune’s EVO756 Phase 2b atopic dermatitis study?

The Phase 2b trial enrolled 121 adults with moderate-to-severe atopic dermatitis. Treatment lasted 12 weeks, with follow-up through Week 14, in a randomized, double-blind, placebo-controlled, dose-ranging design.

Is Evommune (EVMN) discontinuing development of EVO756 entirely?

No. Evommune plans to cease development of EVO756 for atopic dermatitis but will continue to evaluate EVO756 in migraine prophylaxis, as stated in its business and clinical development plans.

What cash runway guidance did Evommune (EVMN) provide in this filing?

Based on current business plans, including revised clinical development plans, Evommune expects its current cash, cash equivalents, and investments will fund operations into 2029. This statement is forward-looking and subject to the risks described in its SEC filings.

What is the recent trading price and exchange listing for Evommune (EVMN) common stock?

Evommune’s common stock is listed on the New York Stock Exchange under the symbol EVMN. On September 8, 2026, the last reported sale price of its common stock was $13.08 per share.

What is the purpose of Evommune’s September 2026 prospectus supplement?

The prospectus supplement updates and supplements the April 24, 2026 prospectus by incorporating information from Evommune’s Form 8-K dated September 8, 2026, which includes the press release on EVO756 Phase 2b top-line results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 06:02 AM Accepted by SEC EDGAR 09/08/2026 - 06:06 PM Learn about SEC filing dates

Prospectus Supplement	Filed Pursuant to Rule 424(b)(3)
(to Prospectus dated April 24, 2026)	Registration No. 333-295140

This prospectus supplement updates, amends and supplements the prospectus dated April 24, 2026 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-295140). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on September 8, 2026, which is set forth below.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, including and supplements and amendments thereto, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Our common stock is traded on the New York Stock Exchange under the symbol “EVMN.” On September 8, 2026, the last reported sale price of our common stock was $13.08 per share.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 5 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is September 8, 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2026

Evommune, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-42938	85-0742575
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1891 Page Mill Road Palo Alto, CA		94304
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (925) 247-4487

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	EVMN	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 8, 2026, Evommune, Inc. (the “Company”) issued a press release titled "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, including Exhibits 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On September 8, 2026, the Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe Atopic Dermatitis (“AD”).

The Phase 2b trial enrolled 121 adults with moderate-to-severe AD over a 12-week treatment period, with follow-up through Week 14. The trial did not meet the primary and secondary endpoints in any of the doses studied. Based on the results of the Phase 2b trial, the Company plans to cease development of EVO756 for AD. The Company will continue to evaluate EVO756 in migraine prophylaxis.

Based on current business plans, including the revised clinical development plans as described in the press release, the Company expects that its current cash, cash equivalents, and investments will be sufficient to fund the Company’s operations into 2029.

Cautionary Note Regarding Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of hereof, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to the Company's continued evaluation of EVO756 in migraine prophylaxis. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, the factors that are described under the caption “Risk Factors” in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 5, 2026, as supplemented by the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 6, 2026, and its subsequent filings with the SEC. The forward-looking statements herein are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release, dated September 8, 2026, titled "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis"
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Evommune, Inc.
Date: September 8, 2026		By:	/s/ Luis Peña
			Luis Peña
			President and Chief Executive Officer